MedTrace Logo

Regulation of Arginine-vasopressin (AVP)

NCT02626832 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-12-10

No results posted yet for this study

Summary

This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia. For this purpose a transitional approach is used based on preclinical studies that show a dose-dependent relationship between the activity of hypothalamic NMDA receptor and plasma AVP response to increasing plasma osmolality. Patients with schizophrenia, depression and healthy controls participated in this study. The Investigators found that in a subgroup of patients with schizophrenia the AVP response was low and that in a subgroup of subjects with depression the AVP response was high compared to healthy controls.

Conditions

Interventions

OTHER

Procedural

All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations

Sponsors & Collaborators

  • VA Connecticut Healthcare System

    collaborator FED

  • The John B. Pierce Laboratory

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Handan Gunduz-Bruce, MD, MBA · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2013-11-30
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626832 on ClinicalTrials.gov